ac-immune-logo-rgb.png
AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year
September 03, 2021 07:52 ET | AC Immune SA
LAUSANNE, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
ac-immune-logo-rgb.png
AC Immune to Participate in Upcoming Virtual Investor Conferences in September
September 02, 2021 07:00 ET | AC Immune SA
LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
ac-immune-logo-rgb.png
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
August 31, 2021 07:30 ET | AC Immune SA
Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11 First evidence of clinical...
ac-immune-logo-rgb.png
AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 04, 2021 07:00 ET | AC Immune SA
Announced strategic acquisition of industry-leading Parkinson’s disease vaccine and equity investment led by key investors in Covid-19 vaccine innovator BioNTech SE ACI-24 full Phase 1b results...
ac-immune-logo-rgb.png
AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson’s Disease at AAIC 2021
July 29, 2021 07:30 ET | AC Immune SA
ACI-24 generated an encouraging immune response that correlated with a signal of target engagement in patients with Down syndrome (DS) Full Phase 1b results support the continued clinical development...
AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH
July 27, 2021 07:30 ET | AC Immune SA
All-stock transaction maintains AC Immune’s strong cash position USD 25 million private placement led by premier investor Athos Service GmbH Transactions expand and accelerate AC Immune’s...
ac-immune-logo-rgb.png
AC Immune Holds its Annual General Meeting of Shareholders
June 25, 2021 08:38 ET | AC Immune SA
LAUSANNE, Switzerland, June 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
ac-immune-logo-rgb.png
AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta
June 02, 2021 07:00 ET | AC Immune SA
Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates Phase 2 interim analysis of ACI-24 confirms good safety and...
ac-immune-logo-rgb.png
AC Immune to Highlight First-in-Class Alzheimer’s Disease Vaccine Programs at Upcoming Investor Conferences
May 20, 2021 07:00 ET | AC Immune SA
LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
ac-immune-logo-rgb.png
AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program Update
May 17, 2021 07:00 ET | AC Immune SA
Previous interim results showing strong safety and potent immunogenicity support trial expansion and advancement of ACI-35.030 into Phase 2b/3 Alternative vaccine candidate also advances to...